Back

Heart failure hospitalisation or cardiovascular death with empagliflozin in patients with type 2 diabetes and high cardiovascular risk: analysis over time in EMPA-REG OUTCOME

23 May 2016 (08:30 - 18:00)
Organised by:
Congress Presentation Part of: Clinical Forum - Mon. 23 May 08:30 - Tues. 24 May 12:30 Acute Heart Failure HFA Premium Access HEART FAILURE 2016

About the speaker

Photo
Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)

22 More presentations in this session

Presentation thumbnail
Zofenopril combined with xanthine oxidase inhibitors may improve survival in post-myocardial infarction patients as compared to placebo or other ACE-inhibitors
Presentation thumbnail
Long-term effects and sustainability of collaborative disease management in systolic heart failure - the extended interdisciplinary network heart failure study
Professor C. Angermann (Wurzburg, DE)
Presentation thumbnail
An implantable pressure sensor for long-term wireless monitoring of cardiac function -first study in man
Doctor J. Baranowski (Linkoping, SE)
Presentation thumbnail
Long-term safety and efficacy of sodium zirconium cyclosilicate (ZS-9) in the treatment of hyperkalaemia: interim analysis of ZS-005, an open-label phase 3 study
Professor S. Anker (Berlin, DE)
Slides
Presentation thumbnail
Characteristics of myocardial deformation parameters and their prognostic impact in patients with hypertrophic cardiomyopathy: a speckle tracking imaging analysis
Doctor S. Charfeddine (Sfax, TN)

Access the full session

Session thumbnail
Clinical Forum - Mon. 23 May 08:30 - Tues. 24 May 12:30

The Event

Event poster

HEART FAILURE 2016

23 May 2016 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Empagliflozin in a real-world chronic heart failure population
3 September 2019
thumbnail
Congress Session
The power of now: a focus on SGLT2 inhibitors for heart failure in the hospital
17 May 2025
thumbnail
Webinar
The HFA Journal Club: win ratio in heart failure trials: for the win?
24 March 2025
thumbnail
Congress Presentation
SGLT-2 inhibitors are associated with lower rates of mortality following myocardial infarction in patients with type 2 diabetes - A SWEDEHEART observational study
27 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources